BeiGene, Ltd. (BGNE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 142.43 |
| Open | 137.79 |
| Bid | 132.40 x 1200 |
| Ask | 136.67 x 800 |
| Day's Range | 132.79 - 138.22 |
| 52 Week Range | 118.18 - 392.30 |
| Volume | |
| Avg. Volume | 230,676 |
| Market Cap | 14.478B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Bloomberg
Latest Push by Chinese Firms to Avoid Delistings Falls Short
(Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneApple Ditches iPhone Production Increase After Demand FaltersStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapMeta to Cut Headcount for First Time, Slash Budgets Across
- Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable. This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales. Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia
- Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
BeiGene Limited (NASDAQ: BGNE) shared updates from its solid tumor development program for tislelizumab at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris. The Phase 3 RATIONALE 301 trial of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma met its primary endpoint of overall survival (OS) non-inferiority. The median OS was 15.9 months for tislelizumab compared to 14.1 months for Bayer AG (OTC: BAYRY) Nexavar (sorafenib). Rela
